Bullishcharts

$CLLS Breakout trade setup inCellectis

Long
NASDAQ:CLLS   Cellectis S.A
Entry level $16 = Target price $19.50 = Stop loss $15
Significant break above 200ma.
Average analysts price target $37 | Buy rating
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

📈Free Chart Analysis on NYSE & NASDAQ-listed Companies

⭐Email Newsletter > https://BullishCharts.com/

🔵Telegram Channel > https://t.me/BullishCharts

🔥YouTube > https://youtube.com/c/BullishCharts

⚡LiveChat > https://discord.gg/BullishCharts